Improving recruitment in preclinical disease trials

Research

Dementia, mainly caused by Alzheimer’s disease (AD), is one of the biggest global public health challenges. It currently affects 50 million people, a figure which is expected to increase to 75 million by 2030.

Alzheimer’s pathophysiological changes start decades before symptom onset, thus opening a window for prevention. Gold standard AD biomarkers (PET and CSF) are invasive and expensive and thus not suitable for screening the general population.

Aim

  • To develop a pre-screening tool based on a new family of machine learning algorithms to predict abnormality of core AD biomarkers from brain MRIs and reduce recruitment expenses by 50%.

Problem to Solve

Identifying cognitively unimpaired individuals who are at risk of developing Alzheimer’s and who could benefit from investigational therapies is challenging. Standard techniques to identify abnormal biomarkers are expensive and invasive. As a consequence, recruitment constitutes a major barrier to the investigation of preventive interventions for Alzheimer’s disease.

Innovation

A family of machine learning algorithms has been developed to predict abnormal Alzheimer’s disease biomarkers from MRI scans at no additional cost. This is intended to be used as a pre-screening tool, to prevent individuals with a low likelihood of having abnormal biomarkers from undergoing expensive and invasive tests. Preliminary results show that, even though predictive power is limited, recruitment costs can be reduced to 47% and participant burden by up to 63%.

Team

Project leader. Group Leader - Neuroimaging

Juan Domingo Gispert

Barcelonaβeta Brain Research Center

Project leader

Alzheimer’s Prevention Programme Scientific Director

José Luis Molinuevo

Barcelonaβeta Brain Research Center

Image Processing Group Leader

V. Vilaplana

UPC - Universitat Politècnica de Catalunya

Managing Director

Glòria Oliver

Barcelonaβeta Brain Research Center

Life Sciences Director

Esther Riambau Riambau

UPF Ventures

Project Manager

Carolina Minguillón

Barcelonaβeta Brain Research Center

MENTOR

Managing Director at Neuroelectrics

Yolanda Casas

Neuroelectrics

Partners

Obra social “la Caixa”
Caixa Capital Risc
Validate-19

Scientific Area

Preventive medicine

Business area

Digital Health

Research center

Barcelonaβeta Brain Research Center